Logo image
IRO Home Research units Researcher Profiles
Sign in
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Journal article   Open access   Peer reviewed

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Kevan C Herold, Brian N Bundy, S Alice Long, Jeffrey A Bluestone, Linda A DiMeglio, Matthew J Dufort, Stephen E Gitelman, Peter A Gottlieb, Jeffrey P Krischer, Peter S Linsley, …
The New England journal of medicine, Vol.381(7), pp.603-613
08/15/2019
DOI: 10.1056/NEJMoa1902226
PMCID: PMC6776880
PMID: 31180194
url
https://doi.org/10.1056/NEJMoa1902226View
Published (Version of record) Open Access

Abstract

Adolescent Adult Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use CD3 Complex - antagonists & inhibitors Child Diabetes Mellitus, Type 1 - genetics Diabetes Mellitus, Type 1 - immunology Diabetes Mellitus, Type 1 - prevention & control Disease Progression Double-Blind Method Exanthema - chemically induced Female Glucose Tolerance Test HLA-DR3 Antigen HLA-DR4 Antigen Humans Lymphocyte Count Lymphopenia - chemically induced Male Middle Aged Proportional Hazards Models T-Lymphocytes - immunology Young Adult

Details

Logo image